| Typicality: | 0.429 |
| Saliency: | 0.540 |
| in clinical trials | 12 | location |
| in treating patients | 12 | location |
| in the screening process | 11 | other |
| drug → show → promise | 169 |
| drug → show → early promise | 4 |
| negative | neutral | positive |
| 0.122 | 0.313 | 0.565 |
| Raw frequency | 173 |
| Normalized frequency | 0.540 |
| Modifier score | 0.609 |
| Perplexity | 110.167 |